The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP

Neoplasia (United States)

Volumn 18, Issue 6, 2016, Pages 356-370

  Hamilton, Mark P ^a   Rajapakshe, Kimal I ^a   Bader, David A ^a   Cerne, Jasmina Z ^a   Smith, Eric A ^a   Coarfa, Cristian ^a   Hartig, Sean M ^a   McGuire, Sean E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; APC PROTEIN; ARGONAUTE PROTEIN; CENTROMERE PROTEIN F; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MICRORNA; MICRORNA 129; MICRORNA 138; MICRORNA 145; MICRORNA 148A; MICRORNA 185; MICRORNA 203; MICRORNA 204; MICRORNA 28; MICRORNA 326; MICRORNA 539; MICRORNA 590; MICRORNA 9; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ACTIN BINDING PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CDKN1B PROTEIN, HUMAN; MIRN148 MICRORNA, HUMAN; NONHISTONE PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; CROSS LINKING; GENE ONTOLOGY; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LNCAP CELL LINE; MALE; ONCOGENE; PHOTOACTIVATION; PRIORITY JOURNAL; PROSTATE CANCER; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

ARGONAUTE PROTEINS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL PROTEINS, NON-HISTONE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MALE; MICROFILAMENT PROTEINS; MICRORNAS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85010792400     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.04.008     Document Type: Article

References (86)

1. [1] Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. [2] Knudsen, KE, Scher, HI, Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15 (2009), 4792–4798.
3. [3] Chen, CD, Welsbie, DS, Tran, C, Baek, SH, Chen, R, Vessella, R, Rosenfeld, MG, Sawyers, CL, Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004), 33–39.
4. [4] Aparicio, A, Tzelepi, V, Araujo, JC, Guo, CC, Liang, S, Troncoso, P, Logothetis, CJ, Navone, NM, Maity, SN, Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71 (2011), 846–856.
5. [5] Taylor, BS, Schultz, N, Hieronymus, H, Gopalan, A, Xiao, Y, Carver, BS, Arora, VK, Kaushik, P, Cerami, E, Reva, B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (2010), 11–22.
6. [6] Barbieri, CE, Baca, SC, Lawrence, MS, Demichelis, F, Blattner, M, Theurillat, JP, White, TA, Stojanov, P, Van Allen, E, Stransky, N, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44 (2012), 685–689.
7. [7] Grasso, CS, Wu, Y-M, Robinson, DR, Cao, X, Dhanasekaran, SM, Khan, AP, Quist, MJ, Jing, X, Lonigro, RJ, Brenner, JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243.
8. [8] Mitrofanova, A, Aytes, A, Zou, M, Shen, MM, Abate-Shen, C, Califano, A, Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models. Cell Rep 12 (2015), 2060–2071.
9. [9] Aytes, A, Mitrofanova, A, Lefebvre, C, Alvarez, MJ, Castillo-Martin, M, Zheng, T, Eastham, JA, Gopalan, A, Pienta, KJ, Shen, MM, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25 (2014), 638–651.
10. [10] Sharma, A, Yeow, WS, Ertel, A, Coleman, I, Clegg, N, Thangavel, C, Morrissey, C, Zhang, X, Comstock, CE, Witkiewicz, AK, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120 (2010), 4478–4492.
11. [11] Sharma, NL, Massie, CE, Ramos-Montoya, A, Zecchini, V, Scott, HE, Lamb, AD, MacArthur, S, Stark, R, Warren, AY, Mills, IG, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23 (2013), 35–47.
12. [12] Robinson, D, Van Allen, EM, Wu, YM, Schultz, N, Lonigro, RJ, Mosquera, JM, Montgomery, B, Taplin, ME, Pritchard, CC, Attard, G, et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
13. [13] Bartel, DP, MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
14. [14] Hamilton, MP, Rajapakshe, K, Hartig, SM, Reva, B, McLellan, MD, Kandoth, C, Ding, L, Zack, TI, Gunaratne, PH, Wheeler, DA, et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun, 4, 2013, 2730.
15. [15] Fang, YX, Gao, WQ, Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33 (2014), 135–147.
16. [16] Boll, K, Reiche, K, Kasack, K, Morbt, N, Kretzschmar, AK, Tomm, JM, Verhaegh, G, Schalken, J, von Bergen, M, Horn, F, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32 (2012), 277–285.
17. [17] Jalava, SE, Urbanucci, A, Latonen, L, Waltering, KK, Sahu, B, Janne, OA, Seppala, J, Lahdesmaki, H, Tammela, TL, Visakorpi, T, Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 31 (2012), 4460–4471.
18. [18] Saini, S, Majid, S, Yamamura, S, Tabatabai, L, Suh, SO, Shahryari, V, Chen, Y, Deng, G, Tanaka, Y, Dahiya, R, Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 17 (2011), 5287–5298.
19. [19] Murata, T, Takayama, K, Katayama, S, Urano, T, Horie-Inoue, K, Ikeda, K, Takahashi, S, Kawazu, C, Hasegawa, A, Ouchi, Y, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 13 (2010), 356–361.
20. [20] Rokhlin, OW, Scheinker, VS, Taghiyev, AF, Bumcrot, D, Glover, RA, Cohen, MB, MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 7 (2008), 1288–1296.
21. [21] Fujita, Y, Kojima, K, Ohhashi, R, Hamada, N, Nozawa, Y, Kitamoto, A, Sato, A, Kondo, S, Kojima, T, Deguchi, T, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285 (2010), 19076–19084.
22. [22] Chi, SW, Zang, JB, Mele, A, Darnell, RB, Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460 (2009), 479–486.
23. [23] Hafner, M, Landthaler, M, Burger, L, Khorshid, M, Hausser, J, Berninger, P, Rothballer, A, Ascano, M Jr., Jungkamp, AC, Munschauer, M, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141 (2010), 129–141.
24. [24] Dehm, SM, Schmidt, LJ, Heemers, HV, Vessella, RL, Tindall, DJ, Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68 (2008), 5469–5477.
25. [25] Li, Y, Alsagabi, M, Fan, D, Bova, GS, Tewfik, AH, Dehm, SM, Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71 (2011), 2108–2117.
26. [26] Dakubo, GD, Parr, RL, Costello, LC, Franklin, RB, Thayer, RE, Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 59 (2006), 10–16.
27. [27] Hafner, M, Lianoglou, S, Tuschl, T, Betel, D, Genome-wide identification of miRNA targets by PAR-CLIP. Methods 58 (2012), 94–105.
28. [28] Corcoran, DL, Georgiev, S, Mukherjee, N, Gottwein, E, Skalsky, RL, Keene, JD, Ohler, U, PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data. Genome Biol, 12, 2011, R79.
29. [29] Uren, PJ, Bahrami-Samani, E, Burns, SC, Qiao, M, Karginov, FV, Hodges, E, Hannon, GJ, Sanford, JR, Penalva, LO, Smith, AD, Site identification in high-throughput RNA-protein interaction data. Bioinformatics 28 (2012), 3013–3020.
30. [30] Langmead, B, Trapnell, C, Pop, M, Salzberg, SL, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol, 10, 2009, R25.
31. [31] Langmead, B, Salzberg, SL, Fast gapped-read alignment with Bowtie 2. Nat Methods 9 (2012), 357–359.
32. [32] Moore, MJ, Zhang, C, Gantman, EC, Mele, A, Darnell, JC, Darnell, RB, Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nat Protoc 9 (2014), 263–293.
33. [33] Li, H, Handsaker, B, Wysoker, A, Fennell, T, Ruan, J, Homer, N, Marth, G, Abecasis, G, Durbin, R, Genome Project Data Processing, S. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
34. [34] Friedman, RC, Farh, KK, Burge, CB, Bartel, DP, Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19 (2009), 92–105.
35. [35] Lipchina, I, Elkabetz, Y, Hafner, M, Sheridan, R, Mihailovic, A, Tuschl, T, Sander, C, Studer, L, Betel, D, Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes Dev 25 (2011), 2173–2186.
36. [36] Kishore, S, Jaskiewicz, L, Burger, L, Hausser, J, Khorshid, M, Zavolan, M, A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat Methods 8 (2011), 559–564.
37. [37] Haecker, I, Gay, LA, Yang, Y, Hu, J, Morse, AM, McIntyre, LM, Renne, R, Ago HITS-CLIP expands understanding of Kaposi's sarcoma-associated herpesvirus miRNA function in primary effusion lymphomas. PLoS Pathog, 8, 2012, e1002884.
38. [38] Skalsky, RL, Corcoran, DL, Gottwein, E, Frank, CL, Kang, D, Hafner, M, Nusbaum, JD, Feederle, R, Delecluse, HJ, Luftig, MA, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog, 8, 2012, e1002484.
39. [39] Gottwein, E, Corcoran, DL, Mukherjee, N, Skalsky, RL, Hafner, M, Nusbaum, JD, Shamulailatpam, P, Love, CL, Dave, SS, Tuschl, T, et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 10 (2011), 515–526.
40. [40] Farazi, TA, Ten Hoeve, JJ, Brown, M, Mihailovic, A, Horlings, HM, van de Vijver, MJ, Tuschl, T, Wessels, LF, Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol, 15, 2014.
41. [41] Memczak, S, Jens, M, Elefsinioti, A, Torti, F, Krueger, J, Rybak, A, Maier, L, Mackowiak, SD, Gregersen, LH, Munschauer, M, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495 (2013), 333–338.
42. [42] Karginov, FV, Hannon, GJ, Remodeling of Ago2-mRNA interactions upon cellular stress reflects miRNA complementarity and correlates with altered translation rates. Genes Dev 27 (2013), 1624–1632.
43. [43] Xue, Y, Ouyang, K, Huang, J, Zhou, Y, Ouyang, H, Li, H, Wang, G, Wu, Q, Wei, C, Bi, Y, et al. Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell 152 (2013), 82–96.
44. [44] Kameswaran, V, Bramswig, Nuria C, McKenna, Lindsay B, Penn, M, Schug, J, Hand, Nicholas J, Chen, Y, Choi, I, Vourekas, A, Won, K-J, et al. Epigenetic regulation of the DLK1-MEG3 MicroRNA cluster in human type 2 diabetic islets. Cell Metab 19 (2014), 135–145.
45. [45] Boudreau, RL, Jiang, P, Gilmore, BL, Spengler, RM, Tirabassi, R, Nelson, JA, Ross, CA, Xing, Y, Davidson, BL, Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron 81 (2014), 294–305.
46. [46] Luna, JM, Scheel, TK, Danino, T, Shaw, KS, Mele, A, Fak, JJ, Nishiuchi, E, Takacs, CN, Catanese, MT, de Jong, YP, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 160 (2015), 1099–1110.
47. [47] Zhang, X, Zuo, X, Yang, B, Li, Z, Xue, Y, Zhou, Y, Huang, J, Zhao, X, Zhou, J, Yan, Y, et al. MicroRNA directly enhances mitochondrial translation during muscle differentiation. Cell 158 (2014), 607–619.
48. [48] Leung, AK, Young, AG, Bhutkar, A, Zheng, GX, Bosson, AD, Nielsen, CB, Sharp, PA, Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs. Nat Struct Mol Biol 18 (2011), 237–244.
49. [49] Schug, J, McKenna, Lindsay B, Walton, G, Hand, N, Mukherjee, S, Essuman, K, Shi, Z, Gao, Y, Markley, K, Nakagawa, M, et al. Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver. BMC Genomics, 14, 2013.
50. [50] Loeb, GB, Khan, AA, Canner, D, Hiatt, JB, Shendure, J, Darnell, RB, Leslie, CS, Rudensky, AY, Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell 48 (2012), 760–770.
51. [51] Krzywinski, M, Schein, J, Birol, I, Connors, J, Gascoyne, R, Horsman, D, Jones, SJ, Marra, MA, Circos: an information aesthetic for comparative genomics. Genome Res 19 (2009), 1639–1645.
52. [52] Quinlan, AR, Hall, IM, BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26 (2010), 841–842.
53. [53] Robinson, MD, McCarthy, DJ, Smyth, GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
54. [54] Subramanian, A, Tamayo, P, Mootha, VK, Mukherjee, S, Ebert, BL, Gillette, MA, Paulovich, A, Pomeroy, SL, Golub, TR, Lander, ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005), 15545–15550.
55. [55] Kenehisa, M, Goto, S, KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28 (2000), 27–30.
56. [56] Thomas, PD, PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 31 (2003), 334–341.
57. [57] Allo, M, Agirre, E, Bessonov, S, Bertucci, P, Gomez Acuna, L, Buggiano, V, Bellora, N, Singh, B, Petrillo, E, Blaustein, M, et al. Argonaute-1 binds transcriptional enhancers and controls constitutive and alternative splicing in human cells. Proc Natl Acad Sci U S A 111 (2014), 15622–15629.
58. [58] Zamudio, JR, Kelly, TJ, Sharp, PA, Argonaute-bound small RNAs from promoter-proximal RNA polymerase II. Cell 156 (2014), 920–934.
59. [59] Agarwal, V, Bell, GW, Nam, JW, Bartel, DP, Predicting effective microRNA target sites in mammalian mRNAs. eLife, 4, 2015.
60. [60] Garcia, DM, Baek, D, Shin, C, Bell, GW, Grimson, A, Bartel, DP, Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 18 (2011), 1139–1146.
61. [61] Cristofano, AD, Acetis, MD, Koff, A, Cordon-Cardo, C, Pandolfi, PP, Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27 (2001), 222–224.
62. [62] Horman, SR, Janas, MM, Litterst, C, Wang, B, MacRae, IJ, Sever, MJ, Morrissey, DV, Graves, P, Luo, B, Umesalma, S, et al. Akt-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. Mol Cell 50 (2013), 356–367.
63. [63] Malik, R, Khan, AP, Asangani, IA, Cieslik, M, Prensner, JR, Wang, X, Iyer, MK, Jiang, X, Borkin, D, Escara-Wilke, J, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med 21 (2015), 344–352.
64. [64] Yu, J, Yu, J, Mani, RS, Cao, Q, Brenner, CJ, Cao, X, Wang, X, Wu, L, Li, J, Hu, M, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17 (2010), 443–454.
65. [65] Zhao, JC, Yu, J, Runkle, C, Wu, L, Hu, M, Wu, D, Liu, JS, Wang, Q, Qin, ZS, Yu, J, Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res 22 (2012), 322–331.
66. [66] Xu, K, Wu, ZJ, Groner, AC, He, HH, Cai, C, Lis, RT, Wu, X, Stack, EC, Loda, M, Liu, T, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338 (2012), 1465–1469.
67. [67] Johnsson, P, Ackley, A, Vidarsdottir, L, Lui, WO, Corcoran, M, Grander, D, Morris, KV, A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol 20 (2013), 440–446.
68. [68] Hong, L, Lai, M, Chen, M, Xie, C, Liao, R, Kang, YJ, Xiao, C, Hu, WY, Han, J, Sun, P, The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res 70 (2010), 8547–8557.
69. [69] Ostling, P, Leivonen, SK, Aakula, A, Kohonen, P, Makela, R, Hagman, Z, Edsjo, A, Kangaspeska, S, Edgren, H, Nicorici, D, et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71 (2011), 1956–1967.
70. [70] Grimson, A, Farh, KK, Johnston, WK, Garrett-Engele, P, Lim, LP, Bartel, DP, MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27 (2007), 91–105.
71. [71] Dehm, SM, Tindall, DJ, Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18 (2011), R183–R196.
72. [72] Hu, R, Lu, C, Mostaghel, EA, Yegnasubramanian, S, Gurel, M, Tannahill, C, Edwards, J, Isaacs, WB, Nelson, PS, Bluemn, E, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72 (2012), 3457–3462.
73. [73] Marzi, MJ, Puggioni, EM, Dall'Olio, V, Bucci, G, Bernard, L, Bianchi, F, Crescenzi, M, Di Fiore, PP, Nicassio, F, Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation. J Cell Biol 199 (2012), 77–95.
74. [74] Liu, X, Wang, C, Chen, Z, Jin, Y, Wang, Y, Kolokythas, A, Dai, Y, Zhou, X, MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 440 (2011), 23–31.
75. [75] Costello, LC, Franklin, RB, The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 59 (2000), 269–282.
76. [76] Massie, CE, Lynch, A, Ramos-Montoya, A, Boren, J, Stark, R, Fazli, L, Warren, A, Scott, H, Madhu, B, Sharma, N, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30 (2011), 2719–2733.
77. [77] Kim, H, Cho, H, Alexander, R, Patterson, HC, Gu, M, Lo, KA, Xu, D, Goh, VJ, Nguyen, LN, Chai, X, et al. MicroRNAs are required for the feature maintenance and differentiation of brown adipocytes. Diabetes 63 (2014), 4045–4056.
78. [78] Trajkovski, M, Hausser, J, Soutschek, J, Bhat, B, Akin, A, Zavolan, M, Heim, MH, Stoffel, M, MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474 (2011), 649–653.
79. [79] Aschrafi, A, Schwechter, AD, Mameza, MG, Natera-Naranjo, O, Gioio, AE, Kaplan, BB, MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J Neurosci 28 (2008), 12581–12590.
80. [80] Alimirah, F, Panchanathan, R, Chen, J, Zhang, X, Ho, S-M, Choubey, D, Expression of androgen receptor is negatively regulated by p53. Neoplasia 9 (2007), 1152–1159.
81. [81] Cronauer, MV, Schulz, WA, Burchardt, T, Ackermann, R, Burchardt, M, Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23 (2004), 3541–3549.
82. [82] Carver, BS, Chapinski, C, Wongvipat, J, Hieronymus, H, Chen, Y, Chandarlapaty, S, Arora, VK, Le, C, Koutcher, J, Scher, H, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19 (2011), 575–586.
83. [83] Pertega-Gomes, N, Felisbino, S, Massie, CE, Vizcaino, JR, Coelho, R, Sandi, C, Simoes-Sousa, S, Jurmeister, S, Ramos-Montoya, A, Asim, M, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. J Pathol 236 (2015), 517–530.
84. [84] Bosson, AD, Zamudio, JR, Sharp, PA, Endogenous miRNA and Target Concentrations Determine Susceptibility to Potential ceRNA Competition. Mol Cell 56 (2014), 347–359.
85. [85] Gosline, SJ, Gurtan, AM, JnBaptiste, CK, Bosson, A, Milani, P, Dalin, S, Matthews, BJ, Yap, YS, Sharp, PA, Fraenkel, E, Elucidating MicroRNA regulatory networks using transcriptional, post-transcriptional, and histone modification measurements. Cell Rep 14 (2016), 310–319, 10.1016/j.celrep.2015.12.031.
86. [86] La Rocca, G, Olejniczak, SH, Gonzalez, AJ, Briskin, D, Vidigal, JA, Spraggon, L, DeMatteo, RG, Radler, MR, Lindsten, T, Ventura, A, et al. In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA. Proc Natl Acad Sci U S A 112 (2015), 767–772.